Thursday, June 25, 2009
Breast cancer treatment research news:PARP Inhibitors
Here's an article about the PARP Inhibitor treatment research I mentioned in my previous blog post: http://www.medpagetoday.com/HematologyOncology/BreastCancer/14851. It'll be two weeks before we know whether or not I have the BRCA I or II mutation but regardless, the point is that a ton of productive research and treatment options are on the horizon with great promise. That's good news worth celebrating! Edited to add (to answer questions): Right now, the PARP treatment is targeted therapy for those known to have cancer from the BRCA 1 or BRCA 2 gene mutation (which I gave a large amount of blood at UCLA to be tested for and for research purposes) - I'll know in a couple weeks if I fall in that category. It will be interesting to see if I am or not because triple negative cancer often is associated with the gene mutation, but not always, but then again there isn't a very strong history of breast cancer in my family - my maternal grandmother and paternal great aunt. There is LOTS of cancer on my dad's side of my family but not my mom's side. However, even if I do, right now the treatment is only available through clinical trials for which I am not a candidate. But if the remaining trials do well and the treatment(s) pass the necessary tests, they could become available to patients needing it outside of the clinical trial setting within 1-3 years. Also, this is but just one of the new class of drugs being tested for use to battle breast cancer. There are approximately 50 active clinical trials in the U.S. for drugs targeted for triple negative breast cancer. I'm not sure how many drugs/treatment therapies are being studied across those trials, but the fact that they're doing it and have seen some promise, keeps me and others in my situation hopeful and eager to hear more about what's to come.